BACKGROUND:It is known that mitochondria play an important role in certain cancers (prostate, renal, breast, or colorectal) and coronary disease.
These organelles play an essential role in apoptosis and the production of reactive oxygen species; in addition, mtDNA also reveals the history of populations and ancient human migration. All these events and variations in the mitochondrial genome are thought to cause some cancers, including prostate cancer, and also help us to group individuals into common origin groups. The aim of the present study is to analyze the different haplogroups and variations in the sequence in the mitochondrial genome of a southern European population consisting of subjects affected (n = 239) and non-affected (n = 150) by sporadic prostate cancer.
METHODOLOGY AND PRINCIPAL FINDINGS:Using primer extension analysis and DNA sequencing, we identified the nine major European haplogroups and CR polymorphisms. The frequencies of the haplogroups did not differ between patients and control cohorts, whereas the CR polymorphism T16356C was significantly higher in patients with PC compared to the controls (p = 0.029). PSA, staging, and Gleason score were associated with none of the nine major European haplogroups. The CR polymorphisms G16129A (p = 0.007) and T16224C (p = 0.022) were significantly associated with Gleason score, whereas T16311C (p = 0.046) was linked with T-stage.
CONCLUSIONS AND SIGNIFICANCE: Our results do not suggest that mtDNA haplogroups could be involved in sporadic prostate cancer etiology and pathogenesis as previous studies performed in middle Europe population. Although some significant associations have been obtained in studying CR polymorphisms, further studies should be performed to validate these results.
Written by:
Álvarez-Cubero MJ, Saiz Guinaldo M, Martínez-González LJ, Álvarez Merino JC, Cózar Olmo JM, Acosta JA. Are you the author?
Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Facultad de Medicina, Universidad de Granada, Granada, Spain.
Reference: PLoS One. 2012;7(7):e41201.
doi: 10.1371/journal.pone.0041201
PubMed Abstract
PMID: 22815971
UroToday.com Investigative Urology Section
